Aflibercept 8 mg demonstrates superior efficacy over aflibercept 2 mg in eyes with neovascular age-related macular degeneration.

Bayer seeks EMA approval for aflibercept 8 mg for treatment of retinal vein occlusion: Berlin Thursday, April 10, 2025, 16:00 Hrs [IST] Bayer has submitted an application to the E ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Berlin: Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of aflibercept 8 mg (114.3 ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

The study enrolled 52 DME patients with poor vision despite prior anti-VEGF treatment and was randomized equally to receive either 10 μg UBX1325 or 2 mg of REGN’s Eylea. UBX1325 is UNITY ...

Opthea and Uni­ty Biotech­nol­o­gy, which are both de­vel­op­ing new drugs for eye dis­eases, were un­able to beat or match afliber­cept, the stan­dard-of-care treat­ment that Re­gen ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...